Skip to main content
. 2016 May 26;2016(5):CD004815. doi: 10.1002/14651858.CD004815.pub4

Comparison 1. All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Index death 6 8094 Risk Ratio (M‐H, Random, 95% CI) 1.54 [1.02, 2.34]
1.1 Routine glycoprotein IIb/IIIa receptor antagonist use 2 3383 Risk Ratio (M‐H, Random, 95% CI) 1.67 [0.84, 3.31]
1.2 No routine glycoprotein IIb/IIIa receptor antagonist use 4 4711 Risk Ratio (M‐H, Random, 95% CI) 1.48 [0.88, 2.48]
2 Early death 4 4345 Risk Ratio (M‐H, Random, 95% CI) 1.18 [0.70, 2.00]
2.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 2220 Risk Ratio (M‐H, Random, 95% CI) 1.38 [0.76, 2.51]
2.2 No routine glycoprotein IIb/IIIa receptor antagonist use 3 2125 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.31, 3.33]
3 Intermediate death 8 8915 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.64, 1.18]
3.1 Routine glycoprotein IIb/IIIa receptor antagonist use 3 4020 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.66, 1.27]
3.2 No routine glycoprotein IIb/IIIa receptor antagonist use 5 4895 Risk Ratio (M‐H, Random, 95% CI) 0.85 [0.48, 1.49]
4 Late death 3 5467 Risk Ratio (M‐H, Random, 95% CI) 0.90 [0.76, 1.08]
4.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 1200 Risk Ratio (M‐H, Random, 95% CI) 1.11 [0.74, 1.67]
4.2 No routine glycoprotein IIb/IIIa receptor antagonist use 2 4267 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.72, 1.04]
5 Index myocardial infarction 7 8694 Risk Ratio (M‐H, Random, 95% CI) 1.08 [0.65, 1.80]
5.1 Routine glycoprotein IIb/IIIa receptor antagonist use 3 3983 Risk Ratio (M‐H, Random, 95% CI) 0.96 [0.51, 1.83]
5.2 No routine glycoprotein IIb/IIIa receptor antagonist use 4 4711 Risk Ratio (M‐H, Random, 95% CI) 1.22 [0.59, 2.55]
6 Early myocardial infarction 4 4345 Risk Ratio (M‐H, Random, 95% CI) 0.68 [0.43, 1.08]
6.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 2220 Risk Ratio (M‐H, Random, 95% CI) 0.53 [0.35, 0.79]
6.2 No routine glycoprotein IIb/IIIa receptor antagonist use 3 2125 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.52, 1.44]
7 Intermediate myocardial infarction 8 8915 Risk Ratio (M‐H, Random, 95% CI) 0.79 [0.63, 1.00]
7.1 Routine glycoprotein IIb/IIIa receptor antagonist use 3 4020 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.56, 1.60]
7.2 No routine glycoprotein IIb/IIIa receptor antagonist use 5 4895 Risk Ratio (M‐H, Random, 95% CI) 0.73 [0.60, 0.89]
8 Late myocardial infarction 3 5467 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.67, 0.92]
8.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 1200 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.66, 1.55]
8.2 No routine glycoprotein IIb/IIIa receptor antagonist use 2 4267 Risk Ratio (M‐H, Random, 95% CI) 0.75 [0.63, 0.90]
9 Index death or non‐fatal myocardial infarction 4 6618 Risk Ratio (M‐H, Random, 95% CI) 1.14 [0.59, 2.21]
9.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 2220 Risk Ratio (M‐H, Random, 95% CI) 0.77 [0.51, 1.17]
9.2 No routine glycoprotein IIb/IIIa receptor antagonist use 3 4398 Risk Ratio (M‐H, Random, 95% CI) 1.46 [0.75, 2.86]
10 Early death or non‐fatal myocardial infarction 2 2351 Risk Ratio (M‐H, Random, 95% CI) 0.64 [0.45, 0.92]
10.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 2220 Risk Ratio (M‐H, Random, 95% CI) 0.67 [0.48, 0.94]
10.2 No routine glycoprotein IIb/IIIa receptor antagonist use 1 131 Risk Ratio (M‐H, Random, 95% CI) 0.30 [0.06, 1.39]
11 Intermediate death or non‐fatal myocardial infarction 7 7715 Risk Ratio (M‐H, Random, 95% CI) 0.93 [0.71, 1.20]
11.1 Routine glycoprotein IIb/IIIa receptor antagonist use 2 2820 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.59, 1.60]
11.2 No routine glycoprotein IIb/IIIa receptor antagonist use 5 4895 Risk Ratio (M‐H, Random, 95% CI) 0.91 [0.62, 1.32]
12 Intermediate death or non‐fatal myocardial infarction; gender subanalysis 5 6975 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.67, 0.91]
12.1 Male 4 4454 Risk Ratio (M‐H, Random, 95% CI) 0.73 [0.62, 0.87]
12.2 Female 5 2521 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.65, 1.16]
13 Late death or non‐fatal myocardial infarction 3 5467 Risk Ratio (M‐H, Random, 95% CI) 0.89 [0.73, 1.08]
13.1 Routine glycoprotein IIb/IIIa receptor antagonist use 1 1200 Risk Ratio (M‐H, Random, 95% CI) 1.19 [0.87, 1.63]
13.2 No routine glycoprotein IIb/IIIa receptor antagonist use 2 4267 Risk Ratio (M‐H, Random, 95% CI) 0.81 [0.72, 0.92]
14 Intermediate refractory angina 5 8287 Risk Ratio (M‐H, Random, 95% CI) 0.64 [0.52, 0.79]
14.1 Routine glycoprotein IIb/IIIa receptor antagonist use 3 4020 Risk Ratio (M‐H, Random, 95% CI) 0.67 [0.42, 1.08]
14.2 No routine glycoprotein IIb/IIIa receptor antagonist use 2 4267 Risk Ratio (M‐H, Random, 95% CI) 0.57 [0.50, 0.64]
15 Intermediate rehospitalisation 6 6921 Risk Ratio (M‐H, Random, 95% CI) 0.77 [0.63, 0.94]
15.1 Routine glycoprotein IIb/IIIa receptor antagonist use 3 4020 Risk Ratio (M‐H, Random, 95% CI) 0.83 [0.61, 1.14]
15.2 No routine glycoprotein IIb/IIIa receptor antagonist use 3 2901 Risk Ratio (M‐H, Random, 95% CI) 0.71 [0.54, 0.94]